✦ LIBER ✦

A timely re-examination of drug polymorphism in pharmaceutical development and regulation

✍ Scribed by David J.W. Grant; Stephen R. Byrn

Book ID: 113417803
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 68 KB
Volume: 56
Category: Article
ISSN: 0169-409X
DOI: 10.1016/j.addr.2003.12.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmaceutical solid polymorphism in dru

Pharmaceutical solid polymorphism in drug development and regulation

✍ Andre S. Raw; Lawrence X. Yu 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 63 KB

The introduction of new drugs into anaes

The introduction of new drugs into anaesthetic practice: a perspective in pharmaceutical development and regulation

✍ Ian Gilron 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 French ⚖ 666 KB

Test of the pharmaceutical compatibility

Test of the pharmaceutical compatibility of drug substances and pharmaceutical ingredients in drug dosage forms of a specified composition under development

✍ N. A. Épshtein 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 207 KB

PRM7 DRUG DEVELOPMENT AND PHARMACEUTICAL

PRM7 DRUG DEVELOPMENT AND PHARMACEUTICAL PRICING IN THE UNITED STATES: THE INFLUENCE OF DRUG INTENDED OUTCOMES OF DRUG PRICING

✍ A. Iaconi; N. Khalidi; O. Olanrewaju; R. Balkrishnan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

Technological development at the boundar

Technological development at the boundaries of the firm: a knowledge-based examination in drug development

✍ Jeffrey T. Macher; Christopher Boerner 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB

A re-examination of the impact of refere

A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia

✍ Paul Grootendorst; David Stewart 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB 👁 1 views

## Abstract Reference pricing (RP) limits drug plan reimbursement of interchangeable medicines to a reference price, which is typically equal to the price of the lowest‐cost interchangeable drug; any cost above that is borne by the patient. Much of the evidence of the effects of RP comes from ‘befo